Guideline Recommendations for Outpatient Management of Acute Bacterial Prostatitis with Urinary Tract Infection

Initial Empiric Oral Therapy

The European Association of Urology recommends oral fluoroquinolones as first‑line agents—ciprofloxacin 500–750 mg twice daily or levofloxacin 750 mg once daily for 2–4 weeks—provided local fluoroquinolone resistance is < 10 %【1】.
Fluoroquinolones are the only oral antibiotics endorsed for empiric treatment because they achieve reliable prostatic tissue concentrations【1】.
Empiric use of fluoroquinolones must be limited to settings where resistance rates are < 10 %; if resistance exceeds this threshold, alternative regimens should be selected【1】【2】.

Trimethoprim‑sulfamethoxazole 160/800 mg twice daily for 14 days is recommended if the isolate is susceptible【1】.
One dose of intravenous ceftriaxone 1–2 g may be given before switching to oral therapy in patients who appear systemically ill, have high fever, or when oral cephalosporins are thought to provide insufficient prostatic penetration【1】【3】.

A minimum of 14 days of therapy is advised for men in whom prostatitis cannot be excluded, reflecting the need for prolonged tissue exposure【4】【5】.
A shortened 7‑day course may be considered only if the patient has been afebrile for ≥48 hours and is hemodynamically stable【4】.

Obtain urine culture with antimicrobial susceptibility testing in all cases to guide targeted therapy【1】.
Perform a urinalysis for leukocytes, erythrocytes, and nitrites to support the diagnosis of a urinary infection【1】.

Gram‑negative organisms (principally E. coli, Klebsiella, and Pseudomonas) account for 80–97 % of acute bacterial prostatitis cases, and resistance rates are rising in complicated male UTIs【4】【6】.

Hospital admission with broad‑spectrum IV antibiotics (e.g., piperacillin‑tazobactam, ceftriaxone, or cefepime) is indicated for patients who are systemically ill, cannot tolerate oral intake, have urinary retention, possess risk factors for multidrug‑resistant organisms, or are hemodynamically unstable【6】【2】.

After susceptibility results are available, de‑escalate to the narrowest‑spectrum oral agent that remains effective【4】【6】.
Maintain the total treatment duration of at least 14 days (longer if chronic prostatitis is suspected)【4】.
For multidrug‑resistant pathogens, consider oral fosfomycin or consult for IV carbapenem therapy【6】.

Do not use nitrofurantoin, single‑dose oral fosfomycin, or pivmecillinam for empiric prostatitis because efficacy data are insufficient【1】【7】【3】.
Do not prescribe a treatment course shorter than 14 days for male UTIs, as they are automatically classified as complicated infections【4】【5】.
Do not ignore local resistance patterns; fluoroquinolone empiric use is permissible only when resistance is < 10 %【1】.
Do not overlook the possibility of a prostatic abscess—if fever persists beyond 72 hours, obtain imaging studies【1】【3】.